These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22157043)

  • 1. Subcutaneous injection of the HIV-1 fusion inhibitor enfuvirtide (FUZEON) may result in soft-tissue accumulation of Tc-99m MDP.
    Pack LE; Zuckier LS
    Clin Nucl Med; 2012 Jan; 37(1):100-1. PubMed ID: 22157043
    [No Abstract]   [Full Text] [Related]  

  • 2. The optimal use of enfuvirtide.
    Gallant JE
    Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
    [No Abstract]   [Full Text] [Related]  

  • 3. Transiently increased MDP activity in the soft tissue of lower extremity caused by iliofemoral venous thrombosis.
    Yu JQ; Zhuang H; Posteraro A; Reddy S; Alavi A
    Clin Nucl Med; 2005 Nov; 30(11):742-3. PubMed ID: 16237301
    [No Abstract]   [Full Text] [Related]  

  • 4. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 5. Fuzeon: avoiding injection-site reactions.
    AIDS Treat News; 2006; (421):5. PubMed ID: 17405216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle-free Fuzeon in works.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16164388
    [No Abstract]   [Full Text] [Related]  

  • 8. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative administration options for Fuzeon.
    AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338434
    [No Abstract]   [Full Text] [Related]  

  • 10. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

  • 11. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
    Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro characterization of a sustained-release formulation for enfuvirtide.
    Rothstein SN; Huber KD; Sluis-Cremer N; Little SR
    Antimicrob Agents Chemother; 2014; 58(3):1797-9. PubMed ID: 24366751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 14. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
    Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
    HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 17. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel form of amyloid deposited at the site of enfuvirtide injection.
    Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
    J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
    [No Abstract]   [Full Text] [Related]  

  • 19. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.
    Avelino-Silva VI; Li HY; Novaes CT
    AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.